Breaking News

Diseased protein degrader shows mixed results in breast cancer trial

March 11, 2025
Exclusive offer: Have your finger on the pulse of the biotech, pharma, and life science industries with a STAT+ subscription. Get 50% off your first year now.
Damian Dovarganes/AP

STAT+ | Diseased protein degrader shows mixed results in breast cancer trial

Arvinas and Pfizer's drug vepdegestrant reduced the risk of tumor progression more than 40% for an ESR1-mutated population, but not for a broader group.

By Adam Feuerstein


Scientists' suit against top academic publishers lays bare deep frustration over unpaid peer review

Scientists want pay for peer review, freedom to submit to multiple journals. Publishers say their practices have been common for decades

By Jonathan Wosen


Bristol buys out cancer cell therapy partner

Today's biotech news includes a struggling CAR-T partner 2Seventy Bio buyout, investors yet again disappointed by Novo data, and more.

By Elaine Chen



Molly Ferguson/STAT

STAT+ | The numbers that tell a scary story about the state of biotech

In this week's edition of "Adam's Biotech Scorecard," we take a closer look at small-cap biotechs, which are down 17%, on average, over three months.

By Adam Feuerstein


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Cancer Briefing? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.

No comments